Vascular Biogenics Ltd. (VBLT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.4000 |
| Open | 1.4100 |
| Bid | 1.0000 x 800 |
| Ask | 1.6000 x 2200 |
| Day's Range | 1.4006 - 1.4900 |
| 52 Week Range | 1.1000 - 2.5900 |
| Volume | |
| Avg. Volume | 165,891 |
| Market Cap | 103.255M |
| Beta (5Y Monthly) | 1.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4710 |
| Earnings Date | Mar 23, 2022 - Mar 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.30 |
- GlobeNewswire
VBL Therapeutics to Participate in the Jefferies Healthcare Conference
TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview and participate in investor meetings at the upcoming Jefferies Healthcare Conference being held in New York o
- Zacks
Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -8.33% and 42.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV, Israel and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced financial results for the first quar
